Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Adavosertib Demonstrates Greater Progression-Free Survival in RAS-/TP53-Mutant Metastatic Colorectal Cancer

Adavosertib Demonstrates Greater Progression-Free Survival in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 25th 2021, 3:00pm

Adavosertib decreased the risk of disease progression or death by 65% in patients with TP53-/RAS-mutant metastatic colorectal cancer (mCRC).

 Men with Intermediate-Risk Prostate Cancer Experience Improved Sexual Function, Urinary Continence Following MRgFUS Therapy

Men with Intermediate-Risk Prostate Cancer Experience Improved Sexual Function, Urinary Continence Following MRgFUS Therapy

September 24th 2021, 6:00pm

Patients with prostate cancer fared better following treatment with magnetic resonance-guided focused ultrasound focal therapy than with radical prostatectomy or radiation therapy, shows study presented at 2021 AUA Annual Meeting.

Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC

Apalutamide Induces Impressive PSA Response and Solid Adherence Rates in Men with nmCRPC

September 23rd 2021, 6:00pm

Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.

Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer

Balstilimab Zalifrelimab Combination Yields Promising Results in Recurrent/Metastatic Cervical Cancer

September 23rd 2021, 3:00pm

A phase 2 trial presented at the 2021 ESMO Annual Congress showed that Balstilimab plus Zalifrelimab induced superior response rates, duration of responses, and overall survival in patients with recurrent/metastatic cervical cancer.

Anticipating the Future of Polycythemia Vera Treatment: Weighing Efficacy and Toxicity

Anticipating the Future of Polycythemia Vera Treatment: Weighing Efficacy and Toxicity

September 22nd 2021, 6:00pm

An expert presenting at the Society of Hematology Oncology 2021 Annual Conference shared important updates in polycythemia vera (PV) treatment and weighed in on the direction of future treatment.

Pembrolizumab in Addition to Chemo Holds Potential as New SOC in Cervical Cancer Frontline Setting

Pembrolizumab in Addition to Chemo Holds Potential as New SOC in Cervical Cancer Frontline Setting

September 22nd 2021, 2:00pm

Data presented at the 2021 ESMO Congress suggest that pembrolizumab in addition to chemo with or without bevacizumab may become new standard of care in the frontline setting of cervical cancer treatment.

Higher BMI Linked to Superior Survival in mCRPC

Higher BMI Linked to Superior Survival in mCRPC

September 20th 2021, 6:00pm

Obese men are more likely to have improved overall survival following treatment for mCRPC than man who are overweight or normal weight, analysis finds.

Tisotumab Vedotin Combinations May Be Associated with Meaningful Responses in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Combinations May Be Associated with Meaningful Responses in Recurrent/Metastatic Cervical Cancer

September 20th 2021, 2:00pm

Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.

Study Finds Similar Clinical Characteristics in VHL-Mutated and VHL Wild Type Clear Cell RCC

Study Finds Similar Clinical Characteristics in VHL-Mutated and VHL Wild Type Clear Cell RCC

September 18th 2021, 6:00pm

Characteristics such as low positive PD-L1 expression and rare high positive staining were identified in both patients with VHL-mutated and VHL wild type clear cell renal cell carcinoma.

Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer

Dostarlimab Elicits Superior Responses in Patients with High Mutational Burden in Endometrial Cancer

September 17th 2021, 6:00pm

Patients with endometrial cancer and high tumor mutational burden experienced superior overall response rates to the agent dostarlimab than patients with low mutational burden.